Manufacturer of Controlled Substances; Notice of Application, 391 [05-77]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 2 / Tuesday, January 4, 2005 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to 21 CFR 1301.33(a), title
21 of the Code of Federal Regulations
(CFR), this is notice that on September
2, 2004, Eli-Elsohly Laboratories, Inc.,
Mahmoud A. Elsohly Ph.D., 5 Industrial
Park Drive, Oxford, Mississippi 38655,
made application by letter to the Drug
Enforcement Administration (DEA) for
registration as a bulk manufacturer of
Thebaine (9333), a basic class of
controlled substance listed in Schedule
II.
The company plans to manufacture
the listed controlled substance in bulk
for use in analysis and drug test
standards.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration, United
States Department of Justice,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Office
of Liaison and Policy (ODLR) and must
be filed no later than March 7, 2005.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–74 Filed 1–3–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
Notice dated July 28, 2004 and
published in the Federal Register on
August 10, 2004, (69 FR 48522),
Hospira, Inc., 1776 North Centennial
Drive, McPherson, Kansas 67460–1247,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Remifentanil (9739), a basic class of
controlled substance listed in Schedule
II.
The company plans to import the
listed controlled substance for use in
dosage unit manufacturing.
VerDate jul<14>2003
18:02 Jan 03, 2005
Jkt 205001
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Hospira, Inc. to import the basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Hospira, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–60 Filed 1–3–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on October 1,
2004, Houba, Inc., PO Box 190, 16235
State Road 17, Culver, Indiana 46511,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in Schedule
II; and by letter dated October 1, 2004,
to modify its name to Acura
Pharmaceutical Technologies, Inc., and
change the address by removing the P.O.
Box 190.
Drug
Schedule
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substance
may file comments or objections to the
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
391
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration, United
States Department of Justice,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Office
of Liaison and Policy (ODLR) and must
be filed no later than March 7, 2005.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–77 Filed 1–3–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated July 23, 2004 and
published in the Federal Register on
August 10, 2004, (69 FR 48522–48523),
JFC Technologies, LLC, 100 West Main
Street, PO Box 669, Bound Brook, New
Jersey 08805, made application by letter
to the Drug Enforcement Administration
(DEA) to be registered as an importer of
Meperidine-Intermediate-B (9233), a
basic class of controlled substance listed
in Schedule II.
The company plans to import the
listed controlled substance for the
production of other controlled
substances for distribution to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
JFC Technologies, LLC to import the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated JFC
Technologies, LLC to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
E:\FR\FM\04JAN1.SGM
04JAN1
]]>Agencies
[Federal Register Volume 70, Number 2 (Tuesday, January 4, 2005)]
[Notices]
[Page 391]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-77]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on October 1, 2004, Houba, Inc.,
PO Box 190, 16235 State Road 17, Culver, Indiana 46511, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in Schedule II; and by letter dated October 1, 2004,
to modify its name to Acura Pharmaceutical Technologies, Inc., and
change the address by removing the P.O. Box 190.
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Oxycodone (9143)........................... II
Hydrocodone (9193)......................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substance may file comments or objections
to the issuance of the proposed registration pursuant to 21 CFR
1301.33(a).
Any such comments or objections may be addressed, in quintuplicate,
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, United States Department of Justice,
Washington, DC 20537, Attention: DEA Federal Register Representative,
Office of Liaison and Policy (ODLR) and must be filed no later than
March 7, 2005.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-77 Filed 1-3-05; 8:45 am]
BILLING CODE 4410-09-P
